Biosimilars Are Here! How Should Patients Choose Between Originator Biologics And Biosimilars?

By Author: DengYueMed
Total Articles: 2
Comment this article

In recent years, as more and more biosimilars have received regulatory approval, the terms “originator biologics” and “biosimilars” have become increasingly important topics for patients. Particularly in the treatment of cancer, autoimmune diseases, diabetes, and hematological disorders, biologic therapies have become essential treatment options. At the same time, the rapid development of biosimilars has provided patients with more choices than ever before.
When discussing treatment options with their physicians, many patients naturally have questions: What exactly is a biosimilar? How does it differ from an originator biologic? Are its efficacy and safety reliable? And how should patients decide between the two? In fact, as healthcare systems around the world continue to improve access to medicines, biosimilars are becoming an increasingly important component of modern healthcare. Dengyue Pharma, which closely follows global pharmaceutical innovation and patient access to therapies, has observed ...
... that as patents for many blockbuster biologic drugs expire, biosimilars are rapidly entering clinical practice and becoming an important pathway for patients to access advanced treatments.

What Is a Biosimilar?
To understand biosimilars, it is first necessary to understand biologic medicines.
Biologics are medicines produced using living cells, microorganisms, or biotechnology-based processes. Their structures are far more complex than those of traditional chemical drugs. Common examples include monoclonal antibodies, recombinant protein therapies, and certain immunotherapies.
When the patent protection for an originator biologic expires, other manufacturers may develop highly similar versions under strict regulatory standards. These products are known as biosimilars.
It is important to emphasize that biosimilars are not the same as traditional generic drugs. Because biologics are highly complex molecules, they cannot be copied exactly in the way chemical drugs can. Therefore, regulatory authorities require biosimilars to undergo extensive comparative studies to demonstrate that there are no clinically meaningful differences between the biosimilar and the originator product.
In simple terms, biosimilars are not “identical” to originator biologics, but they must be “highly similar” and capable of achieving the same therapeutic outcomes.
Are Biosimilars Effective and Safe?
This is one of the most common concerns among patients.
Some people assume that a lower-priced medicine may offer reduced effectiveness. However, biosimilars are subject to rigorous regulatory evaluation before they can be approved.
Whether in China, the United States, Europe, or other major markets, biosimilars must undergo a series of scientific assessments, including structural analysis, quality comparability studies, pharmacokinetic evaluations, and comparative clinical trials.
Regulatory agencies focus on several key questions:
● Does the biosimilar demonstrate efficacy comparable to the originator biologic?
● Does it have a similar safety profile?
● Are there any new immunogenicity risks?
● Can it achieve the same therapeutic objectives?
Only after sufficient evidence confirms the absence of clinically meaningful differences can a biosimilar receive marketing approval.
Over the past decade, a large number of biosimilars have been approved worldwide, generating substantial real-world clinical experience. Multiple international studies have shown that, within their approved indications, most biosimilars demonstrate efficacy and safety profiles highly consistent with those of their originator biologics.
As a result, patients generally do not need to be overly concerned simply because a medicine is classified as a biosimilar.
Are Originator Biologics Always Better Than Biosimilars?
Many patients tend to assume that originator biologics are inherently superior, but this perception is not entirely accurate.
Originator biologics are innovative medicines that were first developed and brought to market. They are supported by extensive research data and long-term clinical experience. Their development often requires more than a decade of research and substantial investment, which contributes to their strong reputation within the medical community.
However, biosimilars are far more than simple copies. Approved biosimilars must meet stringent regulatory requirements demonstrating comparable efficacy and safety.
For patients, the most important consideration is not whether a medicine is an originator product or a biosimilar, but whether it is appropriate for their specific condition and treatment goals.
In many countries and regions, biosimilars have already been incorporated into clinical practice guidelines and are widely used in routine patient care.
Which Disease Areas Commonly Use Biosimilars?
Today, biosimilars are used across a wide range of therapeutic areas.
In oncology, biosimilars of trastuzumab, bevacizumab, and rituximab are widely used in the treatment of breast cancer, lung cancer, colorectal cancer, lymphoma, and other malignancies.
In autoimmune diseases, biosimilars have become important treatment options for conditions such as:
● Rheumatoid arthritis
● Ankylosing spondylitis
● Psoriasis
● Crohn’s disease
In addition, biosimilars are increasingly used in diabetes management, anemia treatment, and certain rare diseases.
As more innovative biologics lose patent exclusivity, an increasing number of biosimilars are expected to enter the market, providing patients with even broader treatment options.
How Should Patients Make Their Choice?
When deciding between an originator biologic and a biosimilar, patients should take a rational and evidence-based approach.
First and foremost, they should seek guidance from qualified healthcare professionals. Physicians can develop individualized treatment plans based on a patient’s disease status, treatment stage, and previous medication history.
Patients may also wish to consider several important factors:
● Whether the medicine is recommended by current treatment guidelines
● Whether it has received formal regulatory approval
● Insurance or reimbursement coverage availability
● Long-term treatment affordability
● The physician’s experience with the medication
For patients who require ongoing maintenance therapy, treatment sustainability is often more important than simply comparing brand names.
Regardless of whether a patient uses an originator biologic or a biosimilar, medications should always be used according to medical advice, with regular follow-up visits and treatment evaluations.
Future Trends in Biosimilar Development
The global biosimilar market is currently experiencing rapid growth.
As technology advances and regulatory frameworks continue to evolve, several trends are expected to shape the future of biosimilars:
● Continued growth in the number of approved products
● Expansion into additional disease areas
● Increased market competition
● Further reductions in treatment costs
Many countries now view biosimilars as a key strategy for improving healthcare accessibility. For patients, this means greater opportunities to access advanced therapies at a more affordable cost.
Conclusion
The emergence of biosimilars is transforming the global healthcare landscape and reshaping patient access to treatment. They not only improve access to advanced therapies but also help reduce the financial burden associated with long-term treatment.
It is important to understand that biosimilars are not simply “lower-cost versions” of originator biologics. Rather, they are important therapeutic products developed under rigorous scientific standards and regulatory oversight. For patients, there is no universally correct choice between an originator biologic and a biosimilar. The most important factor is selecting the treatment option that best aligns with their medical condition, treatment goals, financial situation, and individual needs under the guidance of healthcare professionals.
As biopharmaceutical technologies continue to advance and clinical experience continues to grow, biosimilars are expected to play an increasingly important role in healthcare systems worldwide, providing more patients with equitable, effective, and affordable access to life-changing treatments.